Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLL
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2017
At a glance
- Drugs CTL 119 (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 18 Dec 2017 Planned End Date changed from 1 Feb 2018 to 1 Oct 2019.
- 18 Dec 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2018.
- 18 Dec 2017 Status changed from recruiting to active, no longer recruiting.